Eurocine Vaccines AB engages in the research and development of nasal influenza vaccine for children and adult. Its technology, Endocine used to develop a patent protected nasal influenza vaccine for children. The company was founded in 1999 and is headquartered in Solna, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company